98%
921
2 minutes
20
Background: Mismatch negativity (MMN) and P3a are event-related potential measures of early auditory information processing that are increasingly used as translational biomarkers in the development of treatments for neuropsychiatric disorders. These responses are reduced in schizophrenia patients over the frontocentral scalp electrodes and are associated with important domains of cognitive and psychosocial functioning. While MMN and P3a responses are generated by a dynamic network of cortical sources distributed across the temporal and frontal brain regions, it is not clear how these sources independently contribute to MMN and P3a at the primary frontocentral scalp electrode or to abnormalities observed in schizophrenia. This study aimed to determine the independent source contributions and characterize the magnitude of impairment in source-level MMN and P3a responses in schizophrenia patients.
Methods: A novel method was applied to back-project the contributions of 11 independent cortical source components to Fz, the primary scalp sensor that is used in clinical studies, in n = 589 schizophrenia patients and n = 449 healthy comparison subjects.
Results: The groups showed comparable individual source contributions underlying both MMN and P3a responses at Fz. Source-level responses revealed an increasing magnitude of impairment in schizophrenia patients from the temporal to more frontal sources.
Conclusions: Schizophrenia patients have a normal architecture of source contributions that are accompanied by widespread abnormalities in source resolved mismatch and P3a responses, with more prominent deficits detected from the frontal sources. Quantification of source contributions and source-level responses accelerates clarification of the neural networks underlying MMN reduction at Fz in schizophrenia patients.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099045 | PMC |
http://dx.doi.org/10.1016/j.ijpsycho.2021.01.005 | DOI Listing |
Eur Arch Psychiatry Clin Neurosci
September 2025
Tianjin Anding Hospital, Institute of Mental Health, Psychiatric Medical Center of Tianjin University, Mental Health Center of Tianjin Medical University, 13 Liulin Road, Tianjin, 300222, China.
Background: Elevated homocysteine levels, known as hyperhomocysteinemia (HHcy), have been implicated in the pathophysiology of schizophrenia. Most prior studies focused on first-episode or acute-phase schizophrenia patients, leaving the prevalence, determinants, and clinical correlates of HHcy in chronic schizophrenia understudied. This study aims to investigate the prevalence and determinants of HHcy in patients with chronic schizophrenia, as well as its clinical correlates.
View Article and Find Full Text PDFPsychiatry Clin Neurosci
September 2025
Pharmacology Unit, Department of Pathology and Experimental Therapeutics, School of Medicine and Health Sciences, Institute of Neurosciences, University of Barcelona, L'Hospitalet de Llobregat, Spain.
Schizophrenia is a complex psychiatric disorder characterized by positive, negative, and general psychopathological symptoms. While antipsychotic drugs are effective for positive symptoms, they provide limited benefit for negative symptoms, which are often persistent and strongly associated with functional disability. Additionally, up to 30% of patients exhibit resistance to current treatments, including clozapine.
View Article and Find Full Text PDFEur J Transl Myol
September 2025
Department of Psychiatry, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran; Health Promotion Research Center, Zahedan University of Medical Sciences, Zahedan, Iran; Community Nursing Research Center, Zahedan University of Medical Sciences, Zahedan.
The complexity of schizophrenia, particularly in cases resistant to traditional pharmacological treatments, poses significant challenges for clinicians and researchers. This systematic review synthesizes existing evidence on the effectiveness of deep brain stimulation in treating treatment-resistant schizophrenia. Utilizing the PRISMA 2020 guidelines, a comprehensive literature search was conducted in March 2025 using the "Connected Papers" tool and other sources such as Web of Science, PubMed, PsycINFO, Embase, and Scopus, focusing on studies related to "deep brain stimulation," "treatment-resistant schizophrenia," and "refractory schizophrenia.
View Article and Find Full Text PDFBrain Behav
September 2025
Faculty of Medicine, Department of Internal Medicine, Psychiatry Unit, King Abdulaziz University, Jeddah, Saudi Arabia.
Introduction: The readmission of individuals with schizophrenia to inpatient care poses a significant challenge for health practitioners, as this tendency has a culminating effect on the patients and their families. The duration of hospitalization of a patient with schizophrenia in a hospital or mental health facility poses a significant burden on mental healthcare systems. This study aimed to assess the length of stay of patients with schizophrenia in a mental health facility.
View Article and Find Full Text PDF